Tekmira to supply Ebola drug to investigators in Africa; Novartis hands MorphoSys a cancer drug-related payment;

@FierceBiotech: Achillion shares rocket up as hep C drug scores a quick 6-week cure. News | Follow @FierceBiotech

@JohnCFierce: My schedule at #JPM15 is now officially packed. Thanks for all the invites. The industry is headed to San Fran. | Follow @JohnCFierce

@DamianFierce: Here's the packaging for $ABBV's Viekira, with handy instructions for each of its four pills. Image | Follow @DamianFierce

> Tekmira Pharmaceuticals ($TKMR) says it will supply its Ebola drug to investigators mounting a study in West Africa. Release

> MorphoSys says that it landed a payment from Novartis ($NVS) in connection with the Phase I study of a HuCAL antibody for cancer. Story

Medical Device News

@FierceMedDev: ICYMI Friday: Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. Story | Follow @FierceMedDev

@EmilyWFierce: ICYMI: U.S. appeals court reduces damages Zimmer must pay Stryker in surgical cleaning wand patent suit. Reuters story | Follow @EmilyWFierce

> Roche continues diagnostics winning streak with Bina Technologies acquisition. News

> NIH launches crowdsourcing challenge to commercialize its neurological medical devices. More

> Medtronic reaches another milestone in developing its artificial pancreas. Article

Pharma News

@FiercePharma: New deer vaccine against mad-cow-like disease may help people too. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICMYI from FiercePharmaManufacturing: AstraZeneca targets U.K. plant for closure. Report | Follow @EricPFierce

@CarlyHFierce: #ICYMI: Deal-happy Actavis eyes Spain's Almirall for European growth. Story | Follow @CarlyHFierce

> AstraZeneca CEO says Pfizer won't come back. Oh, and that $45B goal? It's a stretch. Report

> Sorry, Gilead. AbbVie cuts exclusive hep C deal with Express Scripts. More

CRO News

> Evotec banks $10M from its risk-sharing research projects. News

> PPD partners up with ERT for data collection. Story

> WuXi reaches into the biopharma hubs of Boston and San Francisco. More

> Poland's KCR expands its Euro reach with latest deal. Article

> After CEO's death, Health Decisions brings in a Quintiles vet to lead its transition. Report

Animal Health News

> Zoetis hikes dividend under continued pressure from activist investor Ackman. Report

> Aratana Therapeutics starts new canine study; reports good results on another. News

> Lilly's Elanco disputes local paper's allegations of unsafe pet meds. More

> Putney continues winning streak with launch of generic chewable Rimadyl. Article

> Bayer casts off equine drugs with 'no strategic relevance' to Sanofi's Merial. Story

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.